These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9265351)

  • 41. Sympathetic ophthalmia after ruthenium plaque brachytherapy.
    Ahmad N; Soong TK; Salvi S; Rudle PA; Rennie IG
    Br J Ophthalmol; 2007 Mar; 91(3):399-401. PubMed ID: 17322472
    [No Abstract]   [Full Text] [Related]  

  • 42. Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma.
    Horgan N; Shields CL; Mashayekhi A; Teixeira LF; Materin MA; O'Regan M; Shields JA
    Retina; 2008; 28(7):987-95. PubMed ID: 18698302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Results of Iodine-125 radiotherapy in the treatment of uveal melanoma].
    Caminal Mitjana JM; Quintana Casany M; Pera Fábregas J; Cinos Cope C; Guedea F
    Arch Soc Esp Oftalmol; 2002 Jan; 77(1):29-38. PubMed ID: 11813118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
    Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
    Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina.
    Anastassiou G; Bornfeld N; Schueler AO; Schilling H; Weber S; Fluehs D; Jurklies B; Vij O; Sauerwein W
    Br J Ophthalmol; 2006 Apr; 90(4):447-50. PubMed ID: 16547325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical quality assurance for 106Ru ophthalmic applicators.
    Kaulich TW; Zurheide J; Haug T; Nüsslin F; Bamberg M
    Radiother Oncol; 2005 Jul; 76(1):86-92. PubMed ID: 15972240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiation therapy for uveal malignant melanoma.
    Shields CL; Shields JA; Gündüz K; Freire JE; Mercado G
    Ophthalmic Surg Lasers; 1998 May; 29(5):397-409. PubMed ID: 9599365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Plexiglass replicas for optimizing selection and site of ruthenium 106 applicators].
    Menapace R
    Klin Monbl Augenheilkd; 1990 Jan; 196(1):40-2. PubMed ID: 2313993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (106)Ruthenium brachytherapy for retinoblastoma.
    Abouzeid H; Moeckli R; Gaillard MC; Beck-Popovic M; Pica A; Zografos L; Balmer A; Pampallona S; Munier FL
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):821-8. PubMed ID: 18207660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Late complications after brachytherapy of I-125 uveal melanoma].
    Kowal J; Romanowska-Dixon B
    Klin Oczna; 2016; 118(3):226-30. PubMed ID: 30088387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and technical requirements for proton treatment planning of ocular diseases. The SERAG (South Europe Radiotherapy Group).
    Chauvel P; Sauerwein W; Bornfeld N; Friedrichs W; Brassart N; Courdi A; Hérault J; Pignol JP; Bondiau PY; Malandain G
    Front Radiat Ther Oncol; 1997; 30():133-42. PubMed ID: 9205893
    [No Abstract]   [Full Text] [Related]  

  • 52. 125I plaque brachytherapy for anterior uveal melanomas.
    Lumbroso-Le Rouic L; Charif Chefchaouni M; Levy C; Plancher C; Dendale R; Asselain B; Solignac S; Mazal A; Desjardins L
    Eye (Lond); 2004 Sep; 18(9):911-6. PubMed ID: 15002010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term follow-up after uveal melanoma charged particle therapy.
    Char DH; Kroll SM; Castro J
    Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma.
    Schueler AO; Flühs D; Anastassiou G; Jurklies C; Neuhäuser M; Schilling H; Bornfeld N; Sauerwein W
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1212-21. PubMed ID: 16682139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Retrospective analysis of ruthenium-106 brachytherapy for small and medium-sized malignant melanoma of the posterior choroid].
    Stoffelns BM; Kutzner J; Jochem T
    Klin Monbl Augenheilkd; 2002 Apr; 219(4):216-20. PubMed ID: 12022004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Beta-Curie contact therapy in the conservative treatment of uveal melanoma. Evaluation of the first 100 cases treated].
    Grange JD
    Bull Soc Belge Ophtalmol; 1988; 229():15-21. PubMed ID: 3273250
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of dose rate on clinical course in uveal melanoma after brachytherapy with ruthenium-106.
    Mossböck G; Rauscher T; Winkler P; Kapp KS; Langmann G
    Strahlenther Onkol; 2007 Oct; 183(10):571-5. PubMed ID: 17896089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Local tumor control after 106Ru brachytherapy of choroidal melanoma.
    Damato B; Patel I; Campbell IR; Mayles HM; Errington RD
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):385-91. PubMed ID: 15913907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27.
    Collaborative Ocular Melanoma Study Group
    Ophthalmology; 2007 Jul; 114(7):1363-71. PubMed ID: 17337065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.